Redesign Science

Executive Summary

Redesign Science is a private biotechnology company that combines physics-based atomic-level molecular dynamics simulations with generative AI to discover first-in-class small molecule Targeted Protein Interaction Modulators (TPIMs). Founded in 2017 and headquartered in New York, the company's NUVO™ platform simulates biomolecular systems from first principles, enabling rational design of modulators for challenging protein-protein interactions. Redesign Science focuses on undruggable targets in high unmet need areas, leveraging its physics-first approach to reduce false positives and increase clinical success rates. Currently early-stage and preclinical, the company has no disclosed pipeline or funding details but aims to advance its internal therapeutics pipeline using its proprietary technology. Its approach differentiates from conventional AI drug discovery by emphasizing mechanistic understanding over statistical patterns, potentially offering higher predictivity for novel targets.

Upcoming Catalysts (preview)

• H2 2026Lead optimization data for lead TPIM program in oncology50% success
• 2027Strategic partnership or licensing deal with large pharma30% success
• 2026Peer-reviewed publication validating NUVO platform predictive accuracy60% success